Pierre-Eric Juif

List of Publications by Year
in descending order

27	518	687363 13	677142 22
papers	citations	h-index	g-index

27	27	27	606
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Neurohormonal effects of oxytocin and vasopressin receptor agonists on spinal pain processing in male rats. Pain, 2013, 154, 1449-1456.	4.2	78
2	Accelerated Development of the Dual Orexin Receptor Antagonist ACTâ€541468: Integration of a Microtracer in a Firstâ€inâ€Human Study. Clinical Pharmacology and Therapeutics, 2018, 104, 1022-1029.	4.7	52
3	Clinical pharmacology, efficacy, and safety aspects of sphingosine-1-phosphate receptor modulators. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 879-895.	3.3	49
4	Long-Lasting Spinal Oxytocin Analgesia Is Ensured by the Stimulation of Allopregnanolone Synthesis Which Potentiates GABAA Receptor-Mediated Synaptic Inhibition. Journal of Neuroscience, 2013, 33, 16617-16626.	3.6	42
5	First use of cenerimod, a selective S1P₁receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Science and Medicine, 2019, 6, e000354.	2.7	35
6	Metabolite profiling in early clinical drug development: current status and future prospects. Expert Opinion on Drug Metabolism and Toxicology, 2017, 13, 803-806.	3.3	27
7	Clinical Pharmacology of the Reversible and Potent P2Y₁₂ Receptor Antagonist ACTâ€246475 After Single Subcutaneous Administration in Healthy Male Subjects. Journal of Clinical Pharmacology, 2019, 59, 123-130.	2.0	27
8	Pharmacological rescue of nociceptive hypersensitivity and oxytocin analgesia impairment in a rat model of neonatal maternal separation. Pain, 2018, 159, 2630-2640.	4.2	20
9	Etifoxine analgesia in experimental monoarthritis: A combined action that protects spinal inhibition and limits central inflammatory processes. Pain, 2014, 155, 403-412.	4.2	18
10	Corticosterone analgesia is mediated by the spinal production of neuroactive metabolites that enhance <scp>GABA</scp>ergic inhibitory transmission on dorsal horn rat neurons. European Journal of Neuroscience, 2015, 41, 390-397.	2.6	17
11	Peripheral and central alterations affecting spinal nociceptive processing and pain at adulthood in rats exposed to neonatal maternal deprivation. European Journal of Neuroscience, 2016, 44, 1952-1962.	2.6	17
12	Pain behavior and spinal cell activation due to carrageenan-induced inflammation in two inbred rat strains with differential hypothalamicâ€“pituitaryâ€“adrenal axis reactivity. Physiology and Behavior, 2012, 105, 901-908.	2.1	16
13	Mitigation of Initial Cardiodynamic Effects of the S1P₁ Receptor Modulator Ponesimod Using a Novel Upâ€Titration Regimen. Journal of Clinical Pharmacology, 2017, 57, 401-410.	2.0	16
14	A pharmacokinetic drugâ€“drug interaction study between selexipag and midazolam, a CYP3A4 substrate, in healthy male subjects. European Journal of Clinical Pharmacology, 2017, 73, 1121-1128.	1.9	14
15	Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects. International Journal of Molecular Sciences, 2017, 18, 2636.	4.1	13
16	Effects of multiple-dose ponesimod, a selective S1P₁ receptor modulator, on lymphocyte subsets in healthy humans. Drug Design, Development and Therapy, 2017, Volume11, 123-131.	4.3	12
17	Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thrombosis and Haemostasis, 2021, 121, 755-766.	3.4	9
18	Biocomparison of Three Formulations of the S1P1 Receptor Modulator Ponesimod in Healthy Subjects. Drugs in R and D, 2015, 15, 203-210.	2.2	8

#	Article	IF	Citations
19	Absolute Bioavailability of Ponesimod, a Selective S1P1 Receptor Modulator, in Healthy Male Subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2017, 42, 129-134.	1.6	8
20	Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm. Frontiers in Pharmacology, 2020, 11, 628956.	3.5	8
21	Cardiodynamic Interactions between Two S1P1 Receptor Modulators in an Experimental Clinical Setting: Different Pharmacokinetic Properties as an Opportunity to Mitigate First-Dose Heart Rate Effects. International Journal of Molecular Sciences, 2019, 20, 3232.	4.1	7
22	PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 213-224.	1.8	5
23	A Novel Gradual Up-Titration Regimen Mitigates The First-Dose Effects Of Ponesimod, A Selective S1p1 Receptor Modulator. Clinical Therapeutics, 2015, 37, e36-e37.	2.5	4
24	Influence of Rifampinâ€Mediated Organic Anionâ€Transporting Polypeptide 1B1/1B3 Inhibition on the Pharmacokinetics of Clazosentan. Clinical and Translational Science, 2019, 12, 440-444.	3.1	4
25	Modelling pharmacokinetics and pharmacodynamics of the selective S1P₁ receptor modulator cenerimod in healthy subjects and systemic lupus erythematosus patients. British Journal of Clinical Pharmacology, 2020, 86, 791-800.	2.4	4
26	Association Between Vomiting and QT Hysteresis: Data from a TQT Study with the Endothelin A Receptor Antagonist Clazosentan. AAPS Journal, 2020, 22, 103.	4.4	4
27	Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P1R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects. Clinical and Translational Science, 2021, 14, 143-147.	3.1	4